No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ELDN Eledon Pharmaceuticals
- 2.700
- +0.050+1.89%
Close Jul 19 16:00 ET
- 2.760
- +0.060+2.22%
Post 18:03 ET
103.97MMarket Cap-2195P/E (TTM)
2.770High2.650Low37.38KVolume2.650Open2.650Pre Close100.52KTurnover0.13%Turnover RatioLossP/E (Static)38.51MShares3.34952wk High1.39P/B75.22MFloat Cap1.07052wk Low--Dividend TTM27.86MShs Float4864.865Historical High--Div YieldTTM4.53%Amplitude1.070Historical Low2.689Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Eledon Pharmaceuticals Enacts Key Proposals and Board Changes
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company's management team will be hosting one-on-one meetings at the Leerink Partners
H.C. Wainwright Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Vernon Bernardino maintains $Eledon Pharmaceuticals(ELDN.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rat
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10
Noble Financial analyst Robert LeBoyer maintains $Eledon Pharmaceuticals(ELDN.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate o
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $9
LifeSci Capital analyst Rami Katkhuda maintains $Eledon Pharmaceuticals(ELDN.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of
Express News | Eledon Pharmaceuticals Presents Updated Data On Tegoprubart For Preventing Organ Rejection In Kidney Transplant Patients At American Transplant Congress
Comments
$Eledon Pharmaceuticals(ELDN.US$
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
$Eledon Pharmaceuticals(ELDN.US$
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
$Eledon Pharmaceuticals(ELDN.US$ Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Benzinga· 2 mins ago
Benzinga· 2 mins ago
1
Eledon stands at the cusp of revolutionizing the treatment of life-threatening conditions, marking a new era in biopharmaceutical innovation.
Pull up Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), this company has made headlines with its announcement of securing an oversubscribed $50 million private placement. This strategic financial endeavor is not just a testament to the confidence that institutional and accredited healthcar...
Pull up Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), this company has made headlines with its announcement of securing an oversubscribed $50 million private placement. This strategic financial endeavor is not just a testament to the confidence that institutional and accredited healthcar...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg